💊Takeda notes statement by Shire plc regarding revised proposal and extension of PUSU deadline to May 8, 2018
Cambridge, Mass. April 24, 2018 and Osaka, Japan, April 25, 2018 – Takeda Pharmaceutical Company Limited (“Takeda”) notes the statement made today by Shire plc (“Shire”) confirming that it has received a revised proposal from Takeda regarding a possible offer for Shire.
Takeda confirms that the revised proposal comprises 0.839 new Takeda shares and US$30.33 in cash for each Shire ordinary share (the “Revised Proposal”).
Based on Takeda’s share price of ¥4,923 and the exchange rates of £:¥ of 1:151.51 and £:US$ of 1:1.3945 as at the close of business on April 23, 2018, the Revised Proposal implies an equivalent value of approximately £49 per Shire ordinary share, comprising the equivalent of:
£27.26 in new Takeda shares; and
£21.75 in cash.
Takeda Statement Regarding Shire plc
https://www.takeda.com/newsroom/newsreleases/2018/takeda-statement-regarding-shire-plc2/
Shire says it’s willing to recommend Takeda’s $64 billion offer to shareholders | The Japan Times